Schaeffer's Top Stock Picks for '25

2 Drug Stocks Near Key Technical Levels After ASCO

PBYI and TGTX stocks are both trading near key Fibonacci levels

Jun 5, 2017 at 2:45 PM
facebook X logo linkedin


Biotech stocks Puma Biotechnology Inc (NASDAQ:PBYI) and TG Therapeutics Inc (NASDAQ:TGTX) have had big years, both sporting 2017 gains of more than 180%. Like sector peer Loxo Oncology Inc (NASDAQ:LOXO), PBYI and TGTX are making waves again today, too, following this weekend's American Society of Clinical Oncology (ASCO) annual event. Plus, both stocks are testing key technical levels. 

PBYI Stock Could Have More Upside

Puma stock was last seen 3.7% higher at $84.95, and earlier hit an annual high of $92, after the company presented upbeat data on its cancer drug, neratinib. This has PBYI shares comfortably above the $80-$81 region, which is not only home to their recent highs, but also represents a 23.6% Fibonacci retracement of a decline from the 2014 peak to the 2016 bottom. 

puma biotech

Elsewhere, analysts are mostly bullish on PBYI stock, with four out of five rating it a "strong buy." Plus, even with their recent surge, the shares remain below their average 12-month price target of $89.43. Not everyone's bullish, however. About 8.3 million shares of Puma Biotechnology are controlled by short sellers, which is equal to seven times the stock's average daily trading pace. More gains could ensue if these bears start to throw in the towel. 

The Level to Watch for TGTX Stock

Meanwhile, TG Therapeutics stock jumped out of the gate, but was last seen 5.8% lower at $13.05, as investors consider an update on a combination therapy using its leukemia drug. In fact, the shares earlier hit an annual high of $15.35. The $13.80 area could now be one to watch, as this represents a 61.8% Fibonacci retracement of TGTX's rally from early 2014 to its 2015 peak. 

tgtx stock

Like PBYI, analysts are very bullish on TG Therapeutics, with all seven covering brokerages rating it a "strong buy." Moreover, the shares' consensus 12-month price target stands all the way up at $24.14 -- territory not charted since early 2012. But short interest is extremely elevated, as it would take these bears 12 sessions to cover their positions, based on average daily volumes. 

 
 

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

10 Stock Picks FREE
 
 

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade.  Professional traders have rushed into the market and are making a mint.  Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.

 

 
 

FREE Report Download

 

Follow us on X, Follow us on Twitter